Cell death in cardiovascular system has been reported to be maladaptive. Cardiovascular diseases are the leading cause of death in the world. Aberrant cell death in cardiovascular system is the underlying problem and mechanism for most cardiovascular diseases and fatalities. Recent progress indicated that ...
Cell death in cardiovascular system has been reported to be maladaptive. Cardiovascular diseases are the leading cause of death in the world. Aberrant cell death in cardiovascular system is the underlying problem and mechanism for most cardiovascular diseases and fatalities. Recent progress indicated that more than ten types of cell death have been defined such as intrinsic apoptosis, extrinsic apoptosis, mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic cell death, NETotic cell death, lysosome-dependent cell death, autophagy-dependent cell death, immunogenic cell death, cellular senescence, and mitotic catastrophe. As Hadian and Stockwell outlined recently, numerous new small molecule modulators of regulated necrosis have been developed including 11 necroptosis inhibitors, four pyroptosis (inflammatory cell death) inhibitors, six parthanatos inhibitors, 10 ferroptosis inducers, and seven ferroptosis inhibitors.
To promote cardiovascular therapeutic development of cell death regulation drugs in this domain, here we organize this Research Topic and provide a scientific forum for cardiovascular scientists, cardiologists, ultrasound therapy experts, and cardiovascular surgeons to present their newest findings in characterizing anti-inflammatory, anti-cell death, and cell death modulation effects of cell death regulation therapies for cardiovascular diseases.
Keywords:
Cell Death in Cardiovascular System, Cardiovascular Diseases, Cell Death Regulation Drugs, Small Molecule Modulators of Regulated Necrosis, Anti-inflammatory and Anti-cell Death Therapies
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.